| Literature DB >> 33303794 |
Anne Dariel1,2,3, Lucie Grynberg4, Marie Auger4, Chloé Lefèvre4, Tony Durand4, Philippe Aubert4, Catherine Le Berre-Scoul4, Aurélien Venara4, Etienne Suply4, Marc-David Leclair5, Philine de Vries6, Guillaume Levard7, Benoit Parmentier7, Guillaume Podevin8, Françoise Schmitt8, Véronique Couvrat9, Sabine Irtan10, Erik Hervieux10, Thierry Villemagne11, Hubert Lardy11, Carmen Capito12, Cécile Muller12, Sabine Sarnacki12, Jean-François Mosnier13, Louise Galmiche4,14, Pascal Derkinderen4, Hélène Boudin4, Charlène Brochard4, Michel Neunlist4.
Abstract
In Hirschsprung's disease (HSCR), postoperative course remains unpredictable. Our aim was to define predictive factors of the main postoperative complications: obstructive symptoms (OS) and Hirschsprung-associated enterocolitis (HAEC). In this prospective multicentre cohort study, samples of resected bowel were collected at time of surgery in 18 neonates with short-segment HSCR in tertiary care hospitals. OS and HAEC were noted during postoperative follow-up. We assessed the enteric nervous system and the intestinal epithelial barrier (IEB) in ganglionic segments by combining immunohistochemical, proteomic and transcriptomic approaches, with functional ex vivo analysis of motility and para/transcellular permeability. Ten HSCR patients presented postoperative complications (median follow-up 23.5 months): 6 OS, 4 HAEC (2 with OS), 2 diarrhoea (without OS/HAEC). Immunohistochemical analysis showed a significant 41% and 60% decrease in median number of nNOS-IR myenteric neurons per ganglion in HSCR with OS as compared to HSCR with HAEC/diarrhoea (without OS) and HSCR without complications (p = 0.0095; p = 0.002, respectively). Paracellular and transcellular permeability was significantly increased in HSCR with HAEC as compared to HSCR with OS/diarrhoea without HAEC (p = 0.016; p = 0.009) and HSCR without complications (p = 0.029; p = 0.017). This pilot study supports the hypothesis that modulating neuronal phenotype and enhancing IEB permeability may treat or prevent postoperative complications in HSCR.Entities:
Mesh:
Year: 2020 PMID: 33303794 PMCID: PMC7729910 DOI: 10.1038/s41598-020-78340-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Postoperative complications in HSCR patients and age of onset: obstructive symptoms (OS), Hirschsprung-associated enterocolitis (HAEC) and diarrhoea.
| Patient | Stool consistency | Number of stools | OS | HAEC | Diarrhoea | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes/No | Age at onset of OS (months) | Type | Treatment | Yes/No | Age at HAEC (months) | HAEC score | HAEC severity | Yes/No | |||
| 1 | C | 4/day | Yes | 26 | Faecal loading | Laxatives | No | – | – | – | No |
| 2 | C | 2–3/day | Yes | 21 | Abdominal distension, faecal loading | – | No | – | – | – | No |
| 3 | D | 2/week | Yes | 19 | Straining for defecation, constipation | Laxatives | No | – | – | – | No |
| 4 | D | 2/week | Yes | 16 | Straining for defecation, constipation | Diet | No | – | – | – | No |
| 5 | A and B | 1–4/day | Yes | 2 | Abdominal distension, faecal loading | Washouts, botox, laxatives | Yes | 21 | 10 | 2 | No |
| 6 | B | 2/day | Yes | 4 | Abdominal distension, faecal loading | Washouts, micro-enemas | Yes | 4 | 11 | 2 | No |
| 7 | B | 1–2/day | No | – | – | – | Yes | 2.5 and 4 | 7 and 9 | 2 and 2 | No |
| 8 | C | 1–2/day | No | – | – | – | Yes | 8.5 | 7 | 1 | No |
| 9 | A | 8–10/day | No | – | – | – | No | – | – | – | Yes |
| 10 | A | 5–7/day | No | – | – | – | No | – | – | – | Yes |
The treatment received in case of OS was noted regardless of its efficiency. Stool consistency was evaluated with the Amsterdam stool form scale for not-toilet-trained infants[6] (A = watery, B = soft, C = formed, D = hard). Episodes of HAEC were diagnosed according to the HAEC score (HAEC score ≥ 4)[7,8] and severity was graded from 1 to 3 according to published guidelines[3].
Figure 1Immunohistochemical analysis of myenteric plexus in the 3 HSCR subgroups (white bars) (HSCR patients with obstructive symptoms (OS), with HAEC or diarrhoea (HAEC/D) and without complications (w/oC)) and in ARM (grey bar) patients. (A) Immunohistochemical labeling of myenteric plexus with anti-HuC/D and anti-nNOS antibodies (Scale bar = 100 μm). (B) Number of HuC/D-IR myenteric neurons per ganglion (*p = 0.0011). (C) Number of nNOS-IR myenteric neurons per ganglion (*p = 0.0095; **p = 0.002; ***p = 0.006). (D) Number of non nNOS-IR myenteric neurons per ganglion (*p = 0.019; **p = 0.009; ***p = 0.002). (E) ENS area occupied by tissue surface (*p = 0.007; **p = 0.02; ***p = 0.001). Medians with ranges. ENS: enteric nervous system.
Figure 2Neuromuscular transmission was assessed in colonic circular muscle strips in the 3 HSCR subgroups (white bars) (HSCR patients with obstructive symptoms (OS), with HAEC or diarrhoea (HAEC/D) and without complications (w/oC)) and in ARM (grey bar) patients. (A) EFS-contractile response in basal condition, with l-Name, with l-Name + atropine. (B) Variation of EFS-induced AUC with l-Name (*p = 0.006; **p = 0.02; ***p = 0.02), and (C) with l-Name + atropine. (D) Variation of basal tension level with l-Name, and E) with l-Name + atropine (*p = 0.007; **p = 0.014; ***p = 0.02). Medians with ranges. EFS electrical field stimulation, AUC area under the curve.
Figure 3Glial fibrillary acidic protein (GFAP) expression in the muscular layer of sigmoid colon in the 3 HSCR subgroups (white bars) (HSCR patients with obstructive symptoms (OS), with HAEC or diarrhoea (HAEC/D) and without complications (w/oC)) and in ARM (grey bar) patients. The dividing lines in (A) delineate the position of the cropping performed on the same gel before grouping.. Full-length blots are in Supplementary Material. (A) Immunoblot analysis using an antibody recognizing all GFAP isoforms and trunked forms of the protein (panGFAP) and one specific antibody recognizing intact GFAP isoforms (GFAP N-term). All samples derive from the same blot. (B) PanGFAP expression (all bands and 55 kDa band), (C) PanGFAP 55 kDa band expression (*p = 0.02), and (D) GFAP N-term expression by Western Blot analysis (*p = 0.027; **p = 0.01; ***p = 0.015). Medians with ranges.
Figure 4Paracellular and transcellular permeabilities in the 3 HSCR subgroups (white bars) (HSCR patients with Hirschsprung-associated enterocolitis (HAEC), with obstructive symptoms or diarrhoea (OS/D) and without complications (w/oC)) and in ARM (grey bar) patients. (A) Paracellular permeability measured with sulfonic acid (SA) flux (*p = 0.02; **p = 0.0095; ***p = 0.016), and (B) transcellular permeability measured with and Horse Radish Peroxydase (HRP) flux (*p = 0.013; **p = 0.017; ***p = 0.029). Mucosal expression of (C) caveolin-1 (*p = 0.03; **p = 0.04) and (D) clathrin in Western Blot. Medians with ranges. AU: arbitrary unit.
Figure 5Expression of (A) TNFα expression (*p = 0.02), (B) TLR2 expression (*p = 0.01), and (C) TLR4 expression (*p = 0.02) in qPCR in the 3 HSCR subgroups (white bars) (HSCR patients with Hirschsprung-associated enterocolitis (HAEC), with obstructive symptoms or diarrhoea (OS/D) and without complications (w/oC)) and in ARM (grey bar) patients. Medians with ranges. (D) Correlation between TNFα and TLR2 expressions (r = 0.73; 95% IC 0.48–0.87; p < 0.0001), (E) between TNFα and TLR4 expressions (r = 0.78; 95% IC 0.56–0.89; p < 0.0001), and (F) between TLR4 and TLR2 expressions (r = 0.82; 95% IC 0.63–0.92; p < 0.0001).
Primary antibodies.
| Antibody | Host | Source or reference | Dilution | Method |
|---|---|---|---|---|
| HuC/D | Mouse | INVITROGEN, USA (A-21271) | 1:200 | Immunofluorescence |
| nNOS | Rabbit | ALEXIS BIOCHEMICALS, USA (ALX-210-501) | 1:2000 | Immunofluorescence |
| Calretinin | Rabbit | INVITROGEN, USA (18-0211) | 1:500 | Immunofluorescence |
| ZO-1 | Rabbit | THERMOFISHER SCIENTIFIC, USA (40-2200) | 1:200 | Western Blot |
| Occludin | Rabbit | ABCAM, USA (ab167161) | 1:50,000 | Western Blot |
| Claudin-1 | Rabbit | ABCAM, USA (ab180158) | 1:200 | Western Blot |
| JAMA | Rabbit | BETHYL LABORATORIES, USA (A 302891) | 1:1000 | Western Blot |
| Cingulin | Rabbit | SANTA CRUZ BIOTECHNOLOGY, USA (sc-66831) | 1:500 | Western Blot |
| panGFAP | Rabbit | DAKO, France (Z0334) | 1:2000 | Western Blot |
| GFAP N-term | Mouse | SCBT, USA (F-2) | 1:500 | Western Blot |
| β-Actine | Mouse | SIGMA | 1:10,000 | Western Blot |
HuC/D human neuronal protein, nNOS neuronal nitric oxide synthase, GFAP glial fibrillary acidic protein.
Primers for qPCR analysis.
| Primer | Gene | Sequence (5′–3′) |
|---|---|---|
| h-COX1 | Cyclooxygénase 1 | Up-CACCCATGGGAACCAAAG |
| Lp-TGGGGGTCAGGTATGAACTT | ||
| h-COX2 | Cyclooygénase 2 | TGGGAAGCCTTCTCTAACCTC |
| TCAGGAAGCTGCTTTTTACCTT | ||
| h-HPGDS | Hematopoietic Prostaglandin D synthase | GAGAATGGCTTATTGGTAACTCTGT |
| AAAGACCAAAAGTGTGGTACTGC | ||
| h-LPGDS | Lipocalin prostaglandin D synthase | AGAAGAAGGCGGCGTTGTCC |
| CCACCACTGACACGGAGTAGG | ||
| h-MPGES1 | Microsomal prostaglandin E sykthase-1 | CGCTGCTGGTCATCAAGA |
| CGTGTCTCAGGGCATCCT | ||
| h-TLR2 | Toll-like receptor 2 | CGTTCTCTCAGGTGACTGCTC |
| CCTTTGGATCCTGCTTGC | ||
| h-TLR4 | Toll like receptor 4 | CCATGGCCTTCCTCTCCT |
| TCAGCTCCATGCATTGATAAGT | ||
| h-TLR9 | Toll like receptor 9 | TGTGAAGCATCCTTCCCTGT |
| AGAGACAGCGGGTGCAG | ||
| h-IL1beta | Interleukin beta 1 | GAGCAACAAGTGGTGTTCTCC |
| TTGGGATCTACACTCTCCAGC | ||
| h-IL8 | Interleukin beta 8 | CTGGCCGTGGCTCTCTTGG |
| ATTTCTGTGTTGGCGCAGTGTG | ||
| h-IL10 | Interleukin beta 10 | TGAAAACAAGAGCAAGGCCG |
| GCCACCCTGATGTCTCAGTT | ||
| h-TNFalpha | Tumor necrosis factor alpha | CCCGAGTGACAAGCCTGTAG |
| TGAGGTACAGGCCCTCTGAT | ||
| h-IFNgamma | Interferon gamma | CCAGAGCATCCAAAAGAGTGTGGAG |
| GCTGGCGACAGTTCAGCCATCA |